(Taken from Expert Analysis- ACC)
- This secondary analysis from the EMPEROR-Reduced trial shows that use of empagliflozin reduces the risk of CV death or HF hospitalization, as well as worsening renal function, across the glycemic spectrum in those with HF with reduced ejection fraction.
- This study, in addition to a previous one with dapagliflozin, confirms a benefit of SLGT2is in patients with HF with reduced ejection fraction regardless of diabetes status.
Table 1: Effect of SGLTis in DAPA-HF and EMPEROR-Reduced is consistent in those with and without T2DM
*HR not reported with and without diabetes, but no interaction found for diabetes status and treatment effect of empagliflozin on outcome. DAPA-HF evaluated dapagliflozin, and primary outcome was a composite of cardiovascular death or worsening heart failure as evidenced by hospitalization or outpatient intravenous diuresis. EMPEROR-Reduced evaluated empagliflozin and the primary outcome was a composite of cardiovascular death or hospitalization for heart failure.